"Our extensive
research and human clinical trials have demonstrated
without question that MMF is indeed the first and
only natural-form oral preparation of its kind for
DNA." - Dr. Gerald Haase, M.D.
Gerald M. Haase, M.D. is Chairman of
the Engage Glogal Medical Advisory Board.
He is also Clinical Professor of Surgery
at the University of Colorado, School of Medicine
and Children's Hospital Colorado. Dr. Haase has been
active in clinical research trials for three decades
including collaborations in the design of central
venous access devices, applications of
intra-operative radiation therapy for treatment of
pediatric tumors, evaluation of technical surgical
innovations in adult and childhood cancer, and
development of novel strategies for antioxidant
micronutrient therapy for war fighter protection,
against hazardous exposures, for certain chronic
conditions, and for optimal health, the result of
which is Military Micronutrient Formulation.
He received a
B.A. degree from Johns Hopkins University and his
M.D. degree from Tufts University School of Medicine
and was awarded graduate honors in medical research.
His post-graduate training was at the University of
Colorado, the Children's Hospital Medical Center,
Boston, and the Children's Hospital, Columbus, Ohio.
In clinical practice, he was board certified in
general surgery, pediatric surgery and critical
care. He was Chairman of Pediatric Surgery at
Children’s Hospital Colorado, and consultant
pediatric surgeon to the Department of the Army.
Dr. Haase
served as vice-chairman of the Children's Cancer
Group, a cooperative research consortium of the
National Cancer Institute. He was a member of the
National Board of Directors of the American Cancer
Society and its representative to the Alliance for
Childhood Cancer. He is the author or co-author of
175 scientific publications, holds six U.S. patents
for antioxidant micronutrient therapy and been the
recipient of clinical research grants and contracts
funded at a multi-million dollar cumulative level.
He has served
as an editorial reviewer for numerous journals
including The Journal of Pediatric Surgery, Cancer,
and The American Journal of Diseases of Children and
was a member of the editorial board of The Annals of
Surgical Oncology. Dr. Haase participates with the
International Office of the National Cancer
Institute and has been an examiner in pediatric
surgery for the American Board of Surgery. He is a
member of more than 25 professional societies
including the American Association for Cancer
Research, International College of Surgeons,
American Academy of Pediatrics, New York Academy of
Sciences, American College of Physician Executives,
and is a charter member of the International Society
of Pediatric Surgical Oncology. Dr. Haase is also
Chief Medical Officer of PMC and Chairman of the
Board of Directors of PMC Holdings, Inc. Dr. Gerald
M. Haase - MMF
Presentation
Dr.
James Ehrlich is a Clinical Associate Professor at
the University of Colorado (endocrinology) and was
an Adjunct Assistant Professor in the department of
medicine at the George Washington University Medical
Center
in Washington DC from 1999-2012.
Ehrlich
established Early Detection Technologies, LLC which
advises on best practices involving novel
biomarkers, diagnostic testing and cardiovascular
risk assessment, imaging technologies and radiation
protection. With an Aspen Colorado internist, he
established Aspen Preventive Health, a
cardiometabolic clinical testing program beginning
operations in September 2013. Since 2001, Dr.
Ehrlich has been a medical advisor to Premier
Micronutrient Corporation working with radiation
biologists and anti-oxidant scientists to study and
produce novel patented micronutrient formulations
for biologic radiation and environmental toxin
protection, neurocognitive and general health. In
2013, he was the interim medical director for Level
1 Diagnostics in Colorado, an organization which
brings advanced cardiovascular risk assessment tools
to physician practices in order to personalize and
better target preventive medicine strategies.
Switching
careers from anesthesiology to personalized
preventive/diagnostic medicine with "high tech risk
assessment", he founded and became the medical
director of Colorado Heart and Body Imaging in
Denver, two diagnostic facilities using electron
beam tomography (EBT) and numerous other modalities
for the early detection of coronary and vascular
disease, sleep apnea, osteoporosis and some cancers.
By 2002, Colorado Heart and Body Imaging became the
"nation’s most technologically advanced and
versatile screening center". Beginning in 1999, Dr.
Ehrlich has also medically directed
HeartScanWashington DC, HeartScan Houston and
HeartScan Indiana while consulting for several other
imaging centers nationally.
From 2007 to
2009, Ehrlich had served as the chief medical
officer of Atherotech, a Birmingham-based
cardio-diagnostic laboratory where his primary role
involved the education of physicians in lipid
medicine and the use of genetic, metabolomic and
proteomic biomarkers for primary and secondary
prevention. From 2011-2012, Cardionexus, a
Houston-based affiliate of Panasonic Healthcare
employed Dr. Ehrlich as senior medical advisor for
the launch and promotion of the CardioHealth
workstation, an FDA approved automated vascular
ultrasound device.
Teaching and
communicating new ideas and introducing emerging
technologies to the physician and proactive citizen
have also been an avocation. Considered an authority
in the integration of imaging, physiologic and
laboratory diagnostic technologies with conventional
office based assessment, Dr. Ehrlich has delivered
over 200 lectures to physician audiences on 5
continents and is the course co-director for two
annual symposia on preventive medicine and
preventive cardiology. Over the past 15 years,
Ehrlich has made over 200 appearances on national
and regional TV and radio discussing new methods for
the early detection of disease and emerging concepts
in prevention and personalized medicine. A co-author
of a multimedia CD called "The Physician’s Guide to
Coronary Imaging", he is now editing a preventive
medicine guide for the proactive consumer and
creating a consumer health website—the book and
website will involve 50 of the nation's top
physician experts in preventive medicine.
Involved in
atherosclerosis research with investigators at two
medical schools, Dr. Ehrlich is a founding member of
the Society of Atherosclerosis Imaging and a
co-founder of the Society of Cardiovascular CT. He
is an active contributor to and task force member of
SHAPE--the Society for Heart Attack Prevention and
Eradication. Most of his research has focused on the
monitoring of subclinical atherosclerosis in insulin
resistant states and in Type 1 diabetes. More recent
research involves atherosclerosis in kidney failure
patients and clinical studies involving biologic
radiation protection. In June 2013, Dr, Ehrlich
received the Ambassador of Bergamotto research award
in Calabria Italy for his organization of clinical
studies on an anti-oxidant rich fruit (bergamot). He
is currently studying the cardiometabolic and
hepatic effects of a proprietary extract of the
bergamot citrus fruit.
After
graduating with honors from the Boston University
School of Medicine in 1976 at age 23, he did his
internship and residency training at the University
of Colorado Health Sciences Center where he had been
a Clinical Asst. Professor in the department of
anesthesiology, a specialty he had practiced for
twenty years. In 2009, he created the IDA ("Identify
Disease in Advance") Medical Foundation, a nonprofit
organization whose mission is to provide access to
advanced early detection tests in heart disease and
cancer to individuals, regardless of ability to pay.
As a creative endeavor, James Ehrlich is currently
writing the novel which forms the basis for a
medical detective television drama series treatment
he co-created, currently being "shopped" in Los
Angeles.
